Latest News and Press Releases

ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.

Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.

ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.

Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.

Obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities.

Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.

It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.

ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.

ZyVersa Therapeutics forms new obesity, metabolic and inflammatory disease Scientific Advisory Board.

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024.Obesity with related metabolic complications...